Real-world use of Medtronic Neurovascular devices for acute ischemic stroke
Official title: REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
Run by Medtronic Neurovascular Clinical Affairs · NCT07599904 · Data updated 2026-11-12
This registry tests how Medtronic Neurovascular devices perform in everyday treatment of acute ischemic stroke, across multiple centers and patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Medtronic Neurovascular Clinical Affairs Industry-sponsored |
| Locations | 3 sites (Flint, Michigan and 2 other locations) |
| Status | Recruiting |
| Started | July 13, 2026 |
| Main results expected | July 2031 |
| Study ends | July 2031 |
| Registry record updated | July 28, 2026 |
| Trial ID | NCT07599904 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older who are treated or planned to be treated with a commercially available Medtronic Neurovascular device for acute ischemic stroke.
✕Probably not a fit
Patients who cannot complete follow-up or who are enrolled in conflicting trials may not benefit from the registry findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter, single-arm registry to monitor the safety and effectiveness of commercially available Medtronic Neurovascular devices used during treatment of acute ischemic stroke. It collects observational data on patients treated with mechanical thrombectomy and follows them over time to assess outcomes and any adverse events. The study does not randomize treatments or interventions but aims to provide real-world evidence to supplement existing clinical data. Enrollment includes adults treated or planned to be treated with Medtronic devices and excludes those unable to complete follow-up or exposed to conflicting trials. Sites listed include McLaren Flint, Buffalo General Medical Center, and the University of Texas Health Science Center at Houston.
Why it matters
Potential benefit: Results could help clinicians understand how these devices perform in routine practice and guide decision-making for stroke care.
How similar studies have gone: Prior real-world registries have provided useful safety and performance data for neurovascular devices, though outcomes can vary by setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements. 2. Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device\* during treatment for acute ischemic stroke. 3. Participant is 18 years of age or older. Exclusion Criteria: 1. Participant who may be unable to complete follow-up within the registry. 2. Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study. 3. Participant is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the study results based on Principal Investigator's discretion.
Where it's running
-
McLaren Flint Hospital
Flint, Michigan, United States Recruiting -
Buffalo General Medical Center
Buffalo, New York, United States Recruiting -
University of Texas Health Science Center at Houston
Houston, Texas, United States Recruiting
Study contacts
- Study coordinator: Stephanie Salisbury
- Email: rs.recanovaregistry@medtronic.com
- Phone: 612-979-7251
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Short-Term outside-in nerve stimulation for acute ischemic stroke
This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.
-
Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal
This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.
-
Safety of adding NRICM301 to standard care for adults with acute ischemic stroke
This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.
-
Intracranial Recanalization with LT3001 in Acute Ischemic Stroke
This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.
-
Mobilisation After Endovascular Stroke Treatment
This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.
-
Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes
In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.